Prazosin


Generic Medicine Info
Administration
May be taken with or without food. Starting dose is best taken w/ dinner, at least 2-3 hr before retiring. Maintenance doses may be taken w/ or w/o meals.
Special Precautions
Patient with history of micturition syncope in the treatment of benign prostatic hyperplasia (BPH); CHF due to mechanical obstruction (e.g. aortic valve stenosis, mitral valve stenosis, pulmonary embolism, restrictive pericardial disease); ischaemic heart disease. Cataract surgery patient. Hepatic and moderate to severe renal impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness or weakness, if affected, do not drive or operate machinery. Monitoring Parameters Rule out prostate cancer before initiation of therapy. Monitor blood pressure and cardiac status.
Adverse Reactions
Significant: Syncope (with sudden loss of consciousness), orthostatic hypotension, priapism, prolonged erections, angina, CNS depression, intraoperative floppy iris syndrome. Cardiac disorders: Palpitations. Ear and labyrinth disorders: Vertigo. Eye disorders: Blurred vision. Gastrointestinal disorders: Diarrhoea, nausea, vomiting, dry mouth, constipation. General disorders and administration site conditions: Oedema, lack of energy, weakness. Nervous system disorders: Headache, dizziness, drowsiness, faintness. Psychiatric disorders: Depression, nervousness. Respiratory, thoracic and mediastinal disorders: Dyspnoea, nasal congestion. Skin and subcutaneous tissue disorders: Rash.
Drug Interactions
May cause symptomatic hypotension with phosphodiesterase type-5 (PDE-5) inhibitors (e.g. sildenafil, tadalafil, vardenafil). Additive hypotensive effect with diuretics or other antihypertensive agents.
CIMS Class
Other Antihypertensives
ATC Classification
C02CA01 - prazosin ; Belongs to the class of alpha-adrenoreceptor antagonists, peripherally-acting antiadrenergic agents. Used in the treatment of hypertension.
Disclaimer: This information is independently developed by CIMS based on prazosin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in